Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited.
about
The effects of LPM570065, a novel triple reuptake inhibitor, on extracellular serotonin, dopamine and norepinephrine levels in ratsBeyond the monoaminergic hypothesis: neuroplasticity and epigenetic changes in a transgenic mouse model of depressionHomer1/mGluR5 activity moderates vulnerability to chronic social stressBehavioural profiles in captive-bred cynomolgus macaques: towards monkey models of mental disorders?Pharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters.Enhanced self-administration of the CB1 receptor agonist WIN55,212-2 in olfactory bulbectomized rats: evaluation of possible serotonergic and dopaminergic underlying mechanisms.Behavioural screening of zebrafish using neuroactive traditional Chinese medicine prescriptions and biological targets.Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-OxyazetidineAzapirone 5-HT1A receptor partial agonist treatment for major depressive disorder: systematic review and meta-analysis.The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants.The endocannabinoid/endovanilloid system and depression.Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template.Corticotropin releasing factor-1 receptor antagonism alters the biochemical, but not behavioral effects of repeated interleukin-1β administration.Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?Antidepressant-Like Effects of GM1 Ganglioside Involving the BDNF Signaling Cascade in Mice.Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model.Antidepressant-like activity of the neuropeptide Y Y5 receptor antagonist Lu AA33810: behavioral, molecular, and immunohistochemical evidence.Preclinical discovery of duloxetine for the treatment of depression.Extended-release quetiapine fumarate in the treatment of patients with major depressive disorder: adjunct therapy.Novel agents in development for the treatment of depression.Antidepressant drug development: Focus on triple monoamine reuptake inhibition.Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy.Changes in markers of brain serotonin activity in response to chronic exercise in senior men.Internet abusers associate with a depressive state but not a depressive trait.Subtypes of depression and their overlap in a naturalistic inpatient sample of major depressive disorder.
P2860
Q21132285-674B5D26-AC9B-47EF-87FE-DDD54641119EQ24629465-27A9C5EF-5D62-49C6-A283-DFC114F71AB9Q27311111-94774521-284A-477A-9258-301074B3789FQ27323164-A3B8A0E4-D8B7-4B8E-9EF0-A1B9C6895AAEQ28545209-7A77332D-BB7D-4D2D-9CE1-AD93EDD34F3CQ30574411-8765ADDF-24A0-4CB0-B78A-A1F8A528F66BQ30580754-F1456B03-D92D-43B4-A3A6-F861403B40CEQ34162662-0B746F5F-A05C-4C74-A6A5-8FD14B423163Q34386886-C1F9CE83-099F-4352-A44E-258B2C71C581Q34497909-E5F3D708-F900-4C3E-A3E7-DFF5973FB399Q34567576-F40FFD58-46A9-4B18-AF03-06A1A1BAABD4Q35054544-FBC34E2E-D9C7-40DB-AA02-F7C0F7283BFEQ35380856-94257DC8-6AF3-454E-9BBF-B9BD64430855Q37158450-D5A9D84E-07F5-4137-9405-AF83B1E6C674Q37299377-E75E37E6-5B82-47AF-959D-C1D7827F0463Q37552410-F4459311-161A-49CA-A675-D1D0D7EA51DEQ37604161-C57CAE6E-C90D-426B-BF53-2EB549771E14Q38017215-6D58BA08-3DCA-4C4C-A0C6-DFAE5030FA37Q38157027-C2406A84-A19D-4079-B0D2-3B0C4BE184AFQ38164163-53C18AF7-401A-4AE7-BC89-37062F120206Q38260259-6CF9F66A-B54F-4970-9511-ED3587575F4FQ40156599-CECD83C5-9FFD-4E41-96B4-6CCA01313770Q46199225-64A702B2-C8C7-4A8A-85BA-79379A0F076AQ48389918-9B7945AE-80CD-4631-8046-8E5777EAF2CAQ52808722-738B6F98-B4DA-48FC-AD81-751B3837F6C1
P2860
Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Triple reuptake inhibitors for ...... onoamine hypothesis revisited.
@en
Triple reuptake inhibitors for ...... onoamine hypothesis revisited.
@nl
type
label
Triple reuptake inhibitors for ...... onoamine hypothesis revisited.
@en
Triple reuptake inhibitors for ...... onoamine hypothesis revisited.
@nl
prefLabel
Triple reuptake inhibitors for ...... onoamine hypothesis revisited.
@en
Triple reuptake inhibitors for ...... onoamine hypothesis revisited.
@nl
P2093
P2860
P1476
Triple reuptake inhibitors for ...... onoamine hypothesis revisited.
@en
P2093
Berend Olivier
Jolanda Prins
S Mechiel Korte
P2860
P304
P356
10.1517/13543784.2011.594039
P407
P577
2011-06-20T00:00:00Z